Brain Effects of Escitalopram and Citalopram Using fMRI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00825825|
Recruitment Status : Completed
First Posted : January 21, 2009
Results First Posted : September 3, 2012
Last Update Posted : July 14, 2015
Michael Henry, MD
Information provided by (Responsible Party):
Michael Henry, MD, Steward St. Elizabeth's Medical Center of Boston, Inc.
|Study Design||Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Triple (Participant, Investigator, Outcomes Assessor); Primary Purpose: Treatment|
Antidepressant Activity in Healthy Volunteers
|Recruitment Details||Participants were recruited by advertisement from April 2008 until January 2011.|
|Pre-assignment Details||Participants had their serotonin transporter genotyped. Individuals with a genotype of SS or SLg were not randomized. A total of 85 potential participants were screened. Of those, 21 were excluded on the basis of genotype. Another 28 were determined to be ineligible for other reasons and 6 withdrew prior to randomization.|
Data from several subjects had to be excluded due to one or more fMRI scans with poor data quality (usually high motion) or scheduling problems that prevented a scan from occuring during the specified time window.